Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.
Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.